Indivior price target raised to $22 from $15 at Craig-Hallum

Craig-Hallum raised the firm’s price target on Indivior (INDV) to $22 from $15 and keeps a Buy rating on the shares. The firm sees multiple encouraging signs for Indivior in 2025, with positive readthroughs in 2026 and beyond as well. Script trends show meaningful sequential growth for Sublocade and stabilization in the LAI market, while Suboxone scripts appear flat. This, paired with recent commentary around Suboxone pricing dynamics suggests potential upside to Q2 consensus estimates, Craig-Hallum says. Additionally, the firm highlights potential operational improvements under new CEO Joe Ciaffoni, with expected cost discipline and emphasis on the continued growth of Sublocade.